Merkel Cell Carcinoma, Version 1.2018 Clinical Practice Guidelines in Oncology JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK Bichakjian, C. K., Olencki, T., Aasi, S. Z., Alam, M., Andersen, J. S., Blitzblau, R., Bowen, G. M., Contreras, C. M., Daniels, G. A., Decker, R., Farma, J. M., Fisher, K., Gastman, B., Ghosh, K., Grekin, R. C., Grossman, K., Ho, A. L., Lewis, K. D., Loss, M., Lydiatt, D. D., Messina, J., Nehal, K. S., Nghiem, P., Puzanov, I., Schmults, C. D., Shaha, A. R., Thomas, V., Xu, Y. G., Zic, J. A., Hoffmann, K. G., Engh, A. M. 2018; 16 (6): 742–74


This selection from the NCCN Guidelines for Merkel Cell Carcinoma (MCC) focuses on areas impacted by recently emerging data, including sections describing MCC risk factors, diagnosis, workup, follow-up, and management of advanced disease with radiation and systemic therapy. Included in these sections are discussion of the new recommendations for use of Merkel cell polyomavirus as a biomarker and new recommendations for use of checkpoint immunotherapies to treat metastatic or unresectable disease. The next update of the complete version of the NCCN Guidelines for MCC will include more detailed information about elements of pathology and addresses additional aspects of management of MCC, including surgical management of the primary tumor and draining nodal basin, radiation therapy as primary treatment, and management of recurrence.

View details for DOI 10.6004/jnccn.018.0055

View details for Web of Science ID 000435146500010

View details for PubMedID 29891526